
KANSAS
155 posts












📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $VKTX Viking’s VK2735 Shows Up to 14.7% Weight Loss in 13 Weeks 👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: ➤ 𝐕𝐢𝐤𝐢𝐧𝐠 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 (NASDAQ: VKTX) publishes Phase 2 results in 𝐎𝐛𝐞𝐬𝐢𝐭𝐲 journal. ➤ 𝐕𝐊𝟐𝟕𝟑𝟓 achieved up to 𝟏𝟒.𝟕% 𝐦𝐞𝐚𝐧 𝐰𝐞𝐢𝐠𝐡𝐭 𝐥𝐨𝐬𝐬 at 13 weeks. ➤ 𝐍𝐨 𝐰𝐞𝐢𝐠𝐡𝐭-𝐥𝐨𝐬𝐬 𝐩𝐥𝐚𝐭𝐞𝐚𝐮 observed during treatment period. ➤ Drug is a 𝐝𝐮𝐚𝐥 𝐆𝐋𝐏-𝟏 / 𝐆𝐈𝐏 𝐚𝐠𝐨𝐧𝐢𝐬𝐭, targeting obesity and metabolic disorders. ➤ Phase 2 𝐕𝐄𝐍𝐓𝐔𝐑𝐄 trial met all primary and secondary endpoints. ➤ 𝐒𝐚𝐟𝐞𝐭𝐲 𝐩𝐫𝐨𝐟𝐢𝐥𝐞 favorable; most adverse events mild to moderate. ➤ 𝐕𝐀𝐍𝐐𝐔𝐈𝐒𝐇 𝐏𝐡𝐚𝐬𝐞 𝟑 program underway with two registrational studies. ➤ 𝐕𝐀𝐍𝐐𝐔𝐈𝐒𝐇-𝟏 over-enrolled with ~4,650 obesity patients. ➤ 𝐕𝐀𝐍𝐐𝐔𝐈𝐒𝐇-𝟐 enrolling ~1,100 patients with obesity and type 2 diabetes.

>20x on these in 3 days. Cash them in folks. Sell common against and exercise. Spreads are horrible.




















